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Decynium-22 Enhances SSRI-Induced Antidepressant-Like
Effects in Mice: Uncovering Novel Targets to Treat
Depression
Rebecca E. Horton,1 Deana M. Apple,1,2 W. Anthony Owens,1 Nicole L. Baganz,1 Sonia Cano,2 Nathan C. Mitchell,1
Melissa Vitela,1 Georgianna G. Gould,1 Wouter Koek,2,3* and Lynette C. Daws1,3*
1Departments of Physiology, 2Psychiatry, and 3Pharmacology University of Texas Health Science Center, San Antonio, Texas 78229-3900
Mood disorders cause much suffering and lost productivity worldwide, compounded by the fact that many patients are not
effectively treated by currently available medications. The most commonly prescribed antidepressant drugs are the selective
serotonin (5-HT) reuptake inhibitors (SSRIs), which act by blocking the high-affinity 5-HT transporter (SERT). The increase in
extracellular 5-HT produced by SSRIs is thought to be critical to initiate downstream events needed for therapeutic effects. A
potential explanation for their limited therapeutic efficacy is the recently characterized presence of low-affinity, high-capacity
transporters for 5-HT in brain [i.e., organic cation transporters (OCTs) and plasma membrane monoamine transporter], which
may limit the ability of SSRIs to increase extracellular 5-HT. Decynium-22 (D-22) is a blocker of these transporters, and using this
compound we uncovered a significant role for OCTs in 5-HT uptake in mice genetically modified to have reduced or no SERT
expression (Baganz et al., 2008). This raised the possibility that pharmacological inactivation of D-22-sensitive transporters might
enhance the neurochemical and behavioral effects of SSRIs. Here we show that in wild-type mice D-22 enhances the effects of the
SSRI fluvoxamine to inhibit 5-HT clearance and to produce antidepressant-like activity. This antidepressant-like activity of D-22
was attenuated in OCT3 KO mice, whereas the effect of D-22 to inhibit 5-HT clearance in the CA3 region of hippocampus persisted.
Our findings point to OCT3, as well as other D-22-sensitive transporters, as novel targets for new antidepressant drugs with
improved therapeutic potential.
Introduction
Dysfunction of the serotonin (5-HT) system is thought to under-
lie many affective disorders, primary among them, depression
(Charney et al., 1981). The most commonly prescribed antide-
pressant medications are selective serotonin reuptake inhibitors
(SSRIs). SSRIs act to block activity of the high-affinity serotonin
transporter (SERT) and prevent the uptake of 5-HT from extra-
cellular fluid into nerve terminals (Blakely et al., 1998). The en-
suing increase in extracellular 5-HT is considered to be an
important element in triggering the downstream events needed
to produce therapeutic effects. However, a major problem in the
treatment of depression is that many patients experience modest
or no therapeutic benefit (Kirsch et al., 2008), indicating the need
for alternative approaches to treat individuals who respond
poorly to SSRIs.
Organic cation transporters (i.e., OCT1, OCT2, and OCT3)
and the plasma membrane monoamine transporter (PMAT) are
low-affinity transporters for 5-HT, but unlike SERT, have a high
capacity to transport 5-HT (Gründemann et al., 1998; Engel et al.,
2004; Amphoux et al., 2006; Koepsell et al., 2007; Baganz et al.,
2008; Duan and Wang, 2010). Decynium-22 (D-22) (originally
described by Schömig et al., 1993), is a blocker of OCTs and
PMAT, which inhibits 5-HT uptake into cell lines expressing
OCT1, OCT2, OCT3, or PMAT as well as 5-HT uptake into brain
synaptosomes (Engel et al., 2004; Engel and Wang, 2005; Gasser
et al., 2006; Schömig et al., 2006; Duan and Wang, 2010; Hagan et
al., 2011). These reports raise the possibility that low-affinity,
high-capacity D-22-sensitive transporters for 5-HT may account,
at least in part, for the poor clinical efficacy of SSRIs by prevent-
ing extracellular 5-HT levels reaching those required to trigger
the cascade of downstream events needed for therapeutic benefit
(Daws et al., 2013).
Support for this idea comes from studies in mice genetically
modified to lack SERT or to express half as many SERTs as wild-
type mice. In these SERT mutant mice, administration of D-22
inhibits 5-HT clearance from extracellular fluid in hippocampus
and produces antidepressant-like effects (Baganz et al., 2008). In
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contrast, D-22 does not produce these effects in wild-type mice,
perhaps not surprisingly, since these mice have a full complement
of functioning SERT controlling 5-HT uptake. Thus it appears
that D-22-sensitive uptake mechanisms become more important
in regulating 5-HT uptake and behavior when SERT function is
genetically inactivated or impaired (Baganz et al., 2008). This
raises the possibility that D-22-sensitive transporters for 5-HT
may also play a more prominent role in 5-HT clearance when the
high-affinity SERT is pharmacologically inactivated. If so, by lim-
iting the increase of 5-HT in extracellular fluid that follows treat-
ment with an SSRI, D-22-sensitive transporters could provide a
mechanistic basis for poor therapeutic outcome in many pa-
tients. Thus, blockade of D-22-sensitive transporters might be a
novel way to increase the therapeutic efficacy of currently avail-
able antidepressant drugs. Here we report that D-22 augments
the ability of the SSRI, fluvoxamine, to inhibit 5-HT uptake and
to produce antidepressant-like effects, providing support for
D-22-sensitive transporters as novel targets for new antidepres-
sant drugs.
Materials and Methods
Animals. Adult (60-d-old; 25–30 g) male C57BL/6 mice, or OCT3
knock-out (KO) mice (bred on a C57BL/6 background, originally devel-
oped by Zwart et al. (2001) and generously provided to us by Drs. Kim
Tieu, Bruno Giros, and Sophie Gautron) were used for all experiments.
All animal procedures were in strict accordance with the National Insti-
tutes of Health Guide for the Care and Use of Laboratory Animals. All
measures were taken to limit the number of animals used and to mini-
mize animal discomfort.
High-speed chronoamperometry. In vivo chronoamperometry was per-
formed according to methods described in detail previously (Daws and
Toney, 2007; Baganz et al., 2008). We assemble our own carbon fiber
electrodes and a detailed description can be found in Williams et al.
(2007). Recording electrode/micropipette assemblies were constructed
using a single carbon fiber (30 m diameter; Specialty Materials), which
was sealed inside fused silica tubing (Schott, North America). We based
our procedure for electrode construction on modifications of published
methods (Gerhardt, 1995; Perez and Andrews, 2005). Carbon fiber elec-
trodes were coated with Nafion (5% solution; Aldrich Chemical), to
prevent interference from anionic substances in extracellular fluid as
previously described (Daws and Toney, 2007). Electrodes were tested for
sensitivity to the 5-HT metabolite, 5-hydroxyindoleacetic acid (5-HIAA;
250 M) and calibrated with accumulating concentrations of 5-HT (0 –3
M). Only electrodes displaying a selectivity ratio for 5-HT over 5-HIAA
greater than 500:1 and a linear response (r 2  0.9) to 5-HT were used.
The electrochemical recording assembly consisted of a Nafion-coated,
single carbon fiber electrode attached to a four-barreled micropipette
such that their tips were separated by 200 m. Barrels were filled with
combinations of either 5-HT (200 M), D-22 (10 M), fluvoxamine (400
M), a combination of D-22 and fluvoxamine, or phosphate-buffered
saline (PBS). We elected to use fluvoxamine primarily to allow direct
comparison with over a decade of chronoamperometry data reported in
the literature, including those from our own lab, as well as others who
have used fluvoxamine routinely (Daws et al., 1998; Benmansour et al.,
1999, 2002, 2012; Montañez et al., 2003; Daws et al., 2005; Baganz et al.,
2008). All compounds were prepared in 0.1 M PBS with 100 M ascorbic
acid added as an antioxidant and the pH adjusted to 7.4. The
electrode-micropipette recording assembly was lowered into the CA3
region of the dorsal hippocampus (anteroposterior, 1.94 from breg-
ma; mediolateral, 2.0 from midline; dorsoventral, 2.0 from dura)
(Franklin and Paxinos, 1997) of anesthetized mice. For all experi-
ments, mice were anesthetized by intraperitoneal injection (2 ml/kg
body weight) of a mixture of chloralose (35 mg/kg) and urethane (350
mg/kg). A tube was inserted into the trachea to facilitate breathing and
mice were then placed into a stereotaxic frame. Body temperature was main-
tained at 3637°C by a water circulated heating pad.
High-speed chronoamperometric recordings were made using the
FAST-12 and FAST-16 systems (Quanteon). Oxidation potentials con-
sisted of 100 ms pulses of 0.55 V. Each pulse was separated by a 900 ms
interval during which the resting potential was maintained at 0.0 V.
Voltage at the active electrode was applied with respect to an Ag/AgCl
reference electrode positioned in the extracellular fluid of the ipsilateral
superficial cortex. The oxidation and reduction currents were digitally
integrated during the last 80 ms of each 100 ms voltage pulse.
At the conclusion of the experiment, an electrolytic lesion was made to
mark the placement of the electrode tip. The brain was removed, rapidly
frozen on dry ice, and stored at 80°C until use. At this time brains were
thawed to 15°C and sliced into 20-m-thick sections for histological
verification of electrode localization. Only data from mice in which the
electrode was confirmed to be in the CA3 region of the hippocampus
were included in the analyses.
Effects of local and systemic drug administration on 5-HT clearance.
Exogenous 5-HT was applied into the CA3 region of the hippocampus by
pressure ejection (5–25 psi for 0.25–3.0 s). Advantages of this approach
are that clearance can be measured without an associated “release” com-
ponent and that measurements can be made in vivo with excellent tem-
poral (milliseconds) resolution. Serotonin was pressure ejected into
hippocampus to achieve concentrations at the recording electrode of
0.5 M. Once reproducible 5-HT electrochemical signals were ob-
tained, drug or vehicle was applied either locally into the CA3 region of
hippocampus, or intraperitoneally, before the next application of 5-HT.
For locally administered drugs, 5-HT was pressure ejected 2 min after
drug or vehicle to allow sufficient time for drugs to diffuse to the record-
ing site. Serotonin was applied again at 10 min intervals after drug or
vehicle until the signal returned to predrug status. The 10 min time
interval ensured that each signal produced by local application of 5-HT
had completely cleared before the next ejection of 5-HT, drug or vehicle.
For systemic administration, exogenous 5-HT was applied 30 min fol-
lowing intraperitoneal administration of drugs or vehicle so as to corre-
spond to the timing used in the tail suspension test (TST). Two signal
parameters were analyzed: the peak signal amplitude and the T80 time
course parameter. T80 is defined as the time for the signal to decline by
80% of the peak signal amplitude.
TST. The TST was conducted based on the original description by Steru et
al. (1985). In dose–response studies, mice received an intraperitoneal injec-
tion of D-22 (0.01–0.32 mg/kg), fluvoxamine (0.32–32 mg/kg), or saline. In
drug interaction studies, mice received an intraperitoneal injection of either
D-22 (0.1 or 0.32 mg/kg) or saline 60 min before testing, and received a
second intraperitoneal injection of either fluvoxamine (10 mg/kg) or saline
30 min before testing; immediately after each injection, they were placed in
an observation cage. Thirty minutes after the second injection, the distal end
of the tail was fastened to a flat aluminum (2  0.3  10 cm) bar using
adhesive tape at a 90 degree angle to the longitudinal axis of the mouse tail
and the aluminum bar, with a distance of 3–4 cm between the base of the tail
and the edge of the bar. A hole opposite the taped end of the bar was used to
secure the bar to a hook in the ceiling of a visually isolated white test box
(40  40  40 cm). Each mouse was suspended by its tail for 6 min, allowing
the ventral surface and front and hindlimbs to be video recorded using a
digital camera facing the test box. Total time immobile was measured (in
seconds) during the entire 6 min test period. Immobility was defined as the
absence of initiated movements, and included passive swaying of the body. A
mouse was excluded from the experiments if it climbed and held to its tail or
the aluminum bar for a period of 3 s or longer.
Serotonin syndrome. Mice were given saline or a combination of D-22
and fluvoxamine, using the same doses and injection-test intervals as
used in the drug interaction study in the TST. In addition, separate
groups of mice received 8-hydroxy-2-(di-n-propylamino)tetralin (8-
OH-DPAT, 10 mg/kg), 5-hydroxy-L-tryptophan (5-HTP, 100 mg/kg), or
their vehicles (saline and 5% Tween 80, respectively). Each of the five
groups received two intraperitoneal injections, 30 min apart, as follows:
(1) D-22 followed by fluvoxamine, (2) saline followed by 8-OH-DPAT,
(3) saline followed by 5-HTP, (4) saline followed by saline and (5) saline
followed by 5% Tween 80. Immediately after the first injection, animals
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were placed in a transparent observation cage with a mirror positioned
beneath it to allow simultaneous viewing of both the side and ventral
surface of the mouse. Mice were observed for possible occurrence of
elements of the 5-HT syndrome during five, 6 min periods, starting at 15,
30, 60, 120, and 240 min after the second injection. Each animal was
recorded on video until immediately after the observation period that
started at 120 min. The animal was then returned to the home cage where
it was observed at 240 min. During each 6 min period mice were observed
for the occurrence of the following signs: hindlimb abduction, low body
posture, Straub tail, backward movement, tremor, head weaving, and
forepaw treading, according to methods adapted from Fox et al. (2008).
The presence (1) or absence (0) of each sign was assessed during each min
of the 6 min observation period, allowing an animal to receive, for each of
the signs, a score of 0 – 6 at each observation period and an overall score
of 30 for all five observation periods.
HPLC analysis of D-22 in brain. HPLC was used to assay for D-22 in
brain. D-22 (10 mg/kg) was injected intraperitoneally and mice were
killed 30 min later. Brain tissue for samples, calibrators, and controls
were weighed into polypropylene tubes, then 10 times the volume of a
70% acetonitrile solution was added. Samples were homogenized by son-
ication and then 500 l of each was placed in clean polypropylene tubes.
Twenty microliters of diazepam (10 g/ml) for internal standard was
added to each sample. Next, samples were shaken for 10 min, centrifuged
at 3200 g for 20 min at 18°C in a Beckman Allegra X-15R centrifuge. The
supernatant was decanted into clean tubes, and dried under a stream of
nitrogen. Samples were resuspended with 100 l of mobile phase buffer,
and microfilterfuged at 3200 g for 10 min. Fifty microliters of sample was
injected into the HPLC system.
The HPLC system included a Waters model 510 pump, a Waters
model 717 sample injector, a Waters model 2487 UV detector for HPLC
equipped with a deuterium lamp (320/520 nm), and an Alltima 150
mm  4.6 mm C18 column (5 U). Samples were analyzed at a fixed
wavelength of 520 nm, a time constant of 1 s, and a range of 0.1 AUFS on
the UV detector. The mobile phase contained 65% methanol, and 35% of
a solution of 12 mM KH2PO4, pH 6.7. The flow rate of the mobile phase
was 1.5 ml/min. D-22 eluted at 8.7 min and diazepam at 10.1 min. The
peak area ratio of D-22 and the internal standard diazepam were deter-
mined using the Waters Empower chromatography software. D-22 con-
centration was determined by comparing peak area ratio (D22/
diazepam) against the linear regression of ratios of calibrator samples
from a 6 point calibrator curve. The concentrations of D-22 in brain were
expressed as pg D-22/mg brain wet weight.
High purity-grade acetonitrile and methanol were purchased from
Burdick and Jackson. Water used in the assay was purified with a Milli-Q
Water System (Millipore). Potassium phosphate was obtained from
Fisher Scientific. Hydrochloric acid was obtained from JT Baker Chem-
ical. The internal standard, diazepam, was obtained from Sigma.
Statistics. Statistical analyses were performed using Prism 5.04 (Graph-
Pad). Data were analyzed using one-way ANOVA, followed by Newman–
Keuls or Dunnett’s multiple-comparison tests. All data were expressed as
mean  SEM, and p  0.05 was considered statistically significant.
Drugs. Serotonin, 5-HIAA, fluvoxamine, urethane, -chloralose,
D-22, 8-OH-DPAT HBr, and 5-HTP were purchased from Sigma-
Aldrich. All compounds were injected intraperitoneally in a volume of
5–20 ml/kg. Doses are expressed as mg salt weight per kg body weight.
Results
Intrahippocampally applied D-22 enhances the ability of the
SSRI fluvoxamine to inhibit 5-HT clearance from
extracellular fluid
In wild-type mice, we previously found that D-22 could inhibit
5-HT clearance from CA3 region of hippocampus, but only when
extracellular 5-HT levels were in a range that recruited low-
affinity, high-capacity transporters for 5-HT (Baganz et al., 2008,
2010). At lower, SERT-recruiting 5-HT concentrations, D-22 had
no effect on 5-HT clearance, a result not especially surprising
given the high affinity of SERT for 5-HT. However, in the pres-
ence of an SSRI, we reasoned that D-22-sensitive transporters
may exert a more prominent role in 5-HT uptake and therefore,
limit the ability of SSRIs to prolong the time 5-HT remains in
extracellular fluid. This led us to hypothesize that D-22 should
enhance the inhibiting effect of an SSRI on 5-HT clearance. To
test this hypothesis we used high-speed chronoamperometry, ac-
cording to well established protocols (Daws and Toney, 2007;
Baganz et al., 2008, 2010), to measure clearance of locally applied
5-HT from the CA3 region of the hippocampus of anesthetized
mice, before and after intrahippocampal administration of flu-
voxamine, D-22, both drugs given together, or vehicle. The
amount of fluvoxamine delivered (54 pmol) was based on previ-
ous dose–response studies showing maximal inhibition of 5-HT
clearance at this dose (Baganz et al., 2010). The amount of D-22
delivered (1.4 pmol) is the maximum that can be delivered locally
without interfering with the properties of the carbon fiber re-
cording electrode. D-22 (1.4 pmol) has no effect on 5-HT clear-
ance in the CA3 region of hippocampus in wild-type mice but
inhibits 5-HT clearance in mice lacking SERT, suggesting that the
5-HT clearance inhibiting effect of D-22 is mediated at sites other
than SERT, putatively OCT3 (Baganz et al., 2008). Serotonin was
pressure ejected to achieve reproducible signals with amplitudes
of 0.5 M, a concentration that we have previously found to
recruit predominantly SERT-mediated 5-HT clearance (Daws et
al., 2005; Baganz et al., 2008, 2010). Once reproducible signals
were obtained, drug or vehicle was locally ejected into hippocam-
pus and then 2 min later 5-HT was applied again. Representative
traces are shown in Figure 1A. As expected, and consistent with
other reports using similar methodology (Daws et al., 1998, 2000,
2005; Benmansour et al., 1999, 2002), fluvoxamine prolonged
5-HT clearance time (Fig. 1A,B), without producing any signif-
icant effect on signal amplitude (Fig. 1A,C). Likewise, replicating
our previous study (Baganz et al., 2008), D-22 was without effect
on 5-HT clearance time or signal amplitude (Fig. 1A–C). How-
ever, D-22 robustly increased the ability of fluvoxamine to inhibit
5-HT clearance. This effect was apparent not only in terms of
prolonging 5-HT clearance time (Fig. 1A,B), but also in terms of
increasing the amplitude of the 5-HT signal (Fig. 1A,C). Baseline
(i.e., predrug) T80 values did not differ significantly (p  0.20)
among groups and were 101  9, 116  8, 107  15, and 114 
6 s for vehicle, D-22, fluvoxamine, and D-22fluvoxamine
groups, respectively. One-way ANOVA revealed an effect of
treatment on the percentage change from baseline 5-HT clear-
ance time, driven by significant effects of fluvoxamine, and the
combination of fluvoxamine and D-22 to slow 5-HT clearance
(F(3,35)  12.07; p  0.0001; Fig. 1A,B). Likewise, baseline (i.e.,
predrug) signal amplitude values did not differ significantly (p 
0.50) among groups and were 0.66  0.04, 0.56  0.04, 0.65 
0.04, and 0.58  0.06 M for vehicle, D-22, fluvoxamine, and
D-22fluvoxamine groups, respectively. One-way ANOVA re-
vealed an effect of treatment on the percentage change from base-
line in 5-HT signal amplitude, driven by the marked ability of
fluvoxamine, in combination with D-22, to increase signal am-
plitude (F(3,35)  3.85; p  0.05; Fig. 1A,C).
It is worth noting that we conducted these in vivo electro-
chemical studies in the hippocampus for three key reasons. First,
it is a limbic structure considered to be important in the thera-
peutic response to antidepressant drugs (Campbell and Mac-
queen, 2004). Second, it is a region where mechanisms
contributing to 5-HT clearance in vivo have been best character-
ized to date (Daws et al., 1998, 2000, 2005; Baganz et al., 2008).
Third, and especially relevant to the present study are reports that
D-22-sensitive OCTs and PMAT are located in the hippocampus.
Indeed, the availability of selective antibodies has made it possible
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to map the distribution of OCT subtypes and PMAT in brain
(Amphoux et al., 2006; Dahlin et al., 2007; Vialou et al., 2007;
Baganz et al., 2008; Lamhonwah et al., 2008; Cui et al., 2009;
Gasser et al., 2009; Bacq et al., 2012).
The finding that locally administered D-22 can markedly en-
hance fluvoxamine-induced inhibition of 5-HT clearance in hip-
pocampus suggests that the combination of these drugs might
produce similar effects on 5-HT clearance when administered
systemically and, importantly, enhance the antidepressant-like
effect of fluvoxamine. The next set of experiments was designed
to test this hypothesis.
D-22 enhances fluvoxamine-induced antidepressant-like
effects in the TST
The ability of intrahippocampally applied D-22 to enhance
fluvoxamine-induced inhibition of 5-HT clearance supports the
idea that this drug combination might also produce greater
antidepressant-like effects than either drug given alone. To this
end, we studied the effects of systemic administration of D-22
and fluvoxamine in the TST, which measures antidepressant-like
activity in mice (Steru et al., 1985; Cryan et al., 2005). We then
examined how time spent immobile in the TST related to drug-
induced inhibition of 5-HT clearance in hippocampus.
Consistent with the literature (Fujishiro et al., 2002; Cryan et
al., 2005), fluvoxamine, given 30 min before testing, dose de-
pendently reduced time spent immobile in the TST (Fig. 2A;
F(3,28)  5.75, p  0.01). Previously, we found that 0.001 mg/kg
D-22 decreased immobility in SERT-deficient mice, but not in
wild-type mice, and decreased immobility more extensively at 60
min than at 30 min after intraperitoneal administration (Baganz
et al., 2008). Here, we examined the effects of D-22 60 min after
intraperitoneal administration in wild-type mice at doses ranging
from 0.01 to 0.32 mg/kg. At these doses, D-22 did not signifi-
cantly affect immobility (Fig. 2B; p  0.60). This result was not
especially surprising, given the presence of fully functioning,
high-affinity SERT in these mice, which serve to maintain extra-
cellular 5-HT at concentrations below those where low-affinity,
high-capacity transporters for 5-HT can exert more influence.
Doses 0.32 mg/kg, which in preliminary experiments appeared
to decrease locomotion, were not tested.
To test our hypothesis that D-22 would enhance the
antidepressant-like effect of fluvoxamine, we selected a dose of
each drug that did not produce significant effects on time spent
immobile in the TST (i.e., 0.1 mg/kg D-22, and 10 mg/kg fluvox-
amine given 60 and 30 min before testing, respectively). Consis-
tent with the results shown in Figure 2, treatment with either
D-22 (0.1 mg/kg i.p.) or fluvoxamine (10 mg/kg, i.p.) alone pro-
duced no statistically significant decrease in time spent immo-
bile relative to saline-treated control mice (Fig. 3A). However,
cotreatment with D-22 and fluvoxamine markedly decreased
time spent immobile in the TST (one-way ANOVA, F(3,31) 
6.92, p  0.05).
To examine whether the marked antidepressant-like effect of
the combination of D-22 and fluvoxamine was related to an in-
creased ability of this drug combination to inhibit 5-HT uptake,
we used high-speed chronoamperometry to study 5-HT clear-
ance in the CA3 region of hippocampus under the same doses and
injection-test intervals as used in the TST. Consistent with behav-
ioral data in Figure 3A, D-22 had no effect on clearance of intra-
hippocampally applied 5-HT from extracellular fluid (Fig. 3B).
Interestingly, systemically administered fluvoxamine (10 mg/kg),
which did not produce statistically significant effects in the
TST, robustly inhibited clearance of intrahippocampally ap-
plied 5-HT. D-22 enhanced fluvoxamine-induced inhibition
Figure 1. Local blockade of D-22-sensitive transporters enhances fluvoxamine-induced in-
hibition of 5-HT clearance in mouse hippocampus in vivo. A, Representative oxidation currents
(converted to micromolar values) produced by pressure ejection of 5-HT into the CA3 region of
the hippocampus before (black line) and 2 min after (gray line) local application of saline, D-22
(1.4 pmol), fluvoxamine (54 pmol), or fluvoxamine and D-22 given together. Raw tracings are
superimposed for ease of comparison. Note the marked increase in both clearance time and
signal amplitude after local application of D-22 and fluvoxamine when given together. B, The
effect of hippocampally applied fluvoxamine to slow 5-HT clearance is enhanced by concurrent
administration of D-22; one-way ANOVA with Newman–Keuls post hoc comparison, *p  0.05
versus vehicle. C, Hippocampally applied fluvoxamine, in combination with D-22, increases
5-HT signal amplitude; one-way ANOVA with Newman–Keuls post hoc comparison, *p  0.05
versus vehicle. Data are expressed as mean  SEM percentage of baseline values with n 
9 –10 for each drug treatment.
Figure 2. Fluvoxamine, but not D-22, dose dependently reduces immobility time in the TST.
Time spent immobile was measured in seconds, and was expressed as a percentage of the
corresponding vehicle control group. Time spent immobile for vehicle control groups did not
differ significantly ( p  0.50) and were 116  19 and 118  19 s for fluvoxamine and D-22
control groups, respectively. A, Fluvoxamine, administered 30 min before testing, dose depend-
ently decreased time spent immobile, producing a near maximal effect at the highest dose
tested. B, D-22, given 60 min before testing, had no significant effect on time spent immobile at
any of the doses tested. Data are expressed as mean  SEM, n  7–9 for each dose tested;
one-way ANOVA with Dunnett’s multiple-comparison post hoc test, *p  0.05.
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of 5-HT clearance (one-way ANOVA,
F(3,27)  15.47, p  0.05) and of time
spent immobile in the TST (one-way
ANOVA, F(3,31)  6.92, p  0.05). Thus
our own data (Fig. 3C), and those of
others (David et al., 2003), suggest a
positive correlation between a drug’s
ability to inhibit 5-HT uptake and to
produce antidepressant-like effects.
D-22 crosses the blood– brain barrier
The finding that both intrahippocampal
and peripheral (i.p.) administration of
D-22 produced similar inhibition of 5-HT
clearance in hippocampus suggests that
systemically administered D-22 probably
exerts its effects on 5-HT clearance and
behavior via central actions. To ensure
that D-22 crossed the blood– brain bar-
rier, we quantified D-22 in whole brains of
three mice injected intraperitoneally with
10 mg/kg D-22 and three control mice in-
jected with an equal volume of vehicle.
Thirty minutes after the injection, the
brain concentration of D-22 was 56  27
pg/mg, confirming that D-22 reaches the brain following sys-
temic administration.
D-22 enhances fluvoxamine-induced inhibition of
5-HT clearance without inducing elements of the serotonin
syndrome
Drugs or drug combinations that produce excessive serotonergic
activity can induce the serotonin syndrome (Sternbach, 1991;
Kalueff et al., 2007). In humans, symptoms include hyperther-
mia, tachycardia, and rhabdomyolysis, which can result in death
(Lane and Baldwin, 1997; Ener et al., 2003). Thus, an important
consideration relating to our finding that D-22 enhances the abil-
ity of fluvoxamine to prevent 5-HT reuptake is that this drug
combination conceivably could induce elements of the serotonin
syndrome. In mice the serotonin syndrome consists of hindlimb
abduction, low body posture, Straub tail, tremor, backward
movement, head weaving, and forepaw treading (Fox et al.,
2007). In the present study we treated mice with D-22 and flu-
voxamine using the same doses and injection-test intervals as in
the TST to examine whether this combination of D-22 and flu-
voxamine, which produced maximal antidepressant-like activity,
also induced elements of the serotonin syndrome. Different
groups of mice were treated with either vehicle, 8-OH-DPAT (10
mg/kg i.p.), an agonist at 5-HT1A receptors that produces the
serotonin syndrome in mice (Middlemiss and Fozard, 1983;
Blackburn et al., 1984; Hensler and Truett, 1998; Fox et al., 2007),
or 5-HTP (100 mg/kg i.p.), the precursor to 5-HT that also pro-
duces the serotonin syndrome in mice (Fox et al., 2007, 2008).
Mice were then observed for 6 min periods, starting at 15, 30, 60,
120, and 240 min after the second injection. During each 6 min
observation period, mice were scored at 1 min intervals for the
presence or absence of serotonin syndrome elements, according
to methods adapted from Fox et al., (2007). Results for the ob-
servation period starting 30 min after the second injection (i.e.,
the time corresponding to scoring in the TST) are shown in Table
1. As expected, the positive controls, 8-OH-DPAT and 5-HTP,
produced hindlimb abduction and low body posture. In addi-
tion, 8-OH-DPAT produced Straub tail, tremor, and backward
movement. Essentially none of these signs were observed in
vehicle-treated animals. Importantly, the combination of D-22
and fluvoxamine also did not significantly produce any element
of the serotonin syndrome, at any time during the 6 min test, 30
min following the second injection. Likewise, no elements of the
serotonin syndrome were observed throughout the entire 4 h
observation period following the combination of D-22 and flu-
voxamine, suggesting that at these doses, the combination treat-
ment does not produce side effects typically associated with
excess activation of the serotonin system.
Enhancement by D-22 of fluvoxamine-induced
antidepressant-like effects in the tail suspension test is
attenuated in OCT3 knock-out mice
Our data show that D-22 can enhance the antidepressant-like
activity of fluvoxamine. D-22 has affinity for OCT1, 2, and 3
subtypes as well as PMAT (Amphoux et al., 2006; Schömig et al.,
2006; Koepsell et al., 2007; Duan and Wang, 2010). Our next
studies therefore sought to gain insight into which of these trans-
porters might be necessary for this action of D-22. OCT1 has
limited ability to transport 5-HT and is not densely expressed in
hippocampus (Amphoux et al., 2006; Schömig et al., 2006; Koep-
sell et al., 2007). OCT2 expression in brain is confined primarily
to subventricular regions, though it is expressed in hippocampus
(Wu et al., 1998, 1999; Amphoux et al., 2006; Bacq et al., 2012).
OCT3 and PMAT are richly expressed in limbic regions, includ-
ing hippocampus (Gründemann et al., 1998; Dahlin et al., 2007;
Baganz et al., 2008; Gasser et al., 2009). Based on these reports
and because our previous studies support a role for OCT3 in
mediating the effects of D-22 on immobility time in the TST
(Baganz et al., 2008, 2010), we turned to OCT3 KO mice to in-
vestigate the requirement of this transporter for D-22 to enhance
the effects of fluvoxamine in the TST. Behavioral and neuro-
chemical characterization of OCT3 KO mice has been reported
previously (Vialou et al., 2008, Cui et al., 2009; Wultsch et al.,
2009).
Using the same dosing and timing regimen as before, we
found that like wild-type C57BL/6 mice, D-22 (0.1 mg/kg) and
fluvoxamine (10 mg/kg), when given alone to OCT3 KO mice,
Figure 3. D-22 enhances the antidepressant-like and 5-HT clearance-inhibiting effects of fluvoxamine following systemic
administration in wild-type C57BL/6 mice. A, Doses of D-22 (0.1 mg/kg) and fluvoxamine (10 mg/kg), which by themselves did not
significantly change time spent immobile in the TST compared with saline-injected control mice, markedly decreased immobility
time when given together. Data are expressed as mean  SEM percentage of time (s) immobile under saline control conditions
(112  18 s); n  7–10 per treatment condition; one-way ANOVA, F(3,31)  6.92, p  0.05; Newman–Keuls post hoc test, *p 
0.01. B, In a separate group of mice, using the same doses and injection-test intervals used for the TST, systemic administration of
D-22 enhanced fluvoxamine-induced inhibition of 5-HT clearance in hippocampus. Data are expressed as a percentage of baseline
T80 values (i.e., prevehicle or drug injection T80 clearance times for 5-HT)  SEM; n  6 –9 per treatment condition; one-way
ANOVA, F(3,27)  15.47, p  0.05; Newman–Keuls post hoc test, *p  0.01, **p  0.001 versus saline; #p  0.05 versus
fluvoxamine. C, Regression analysis shows a strong, positive, correlation (r 2  0.95, p  0.025) between the ability of a given
treatment to inhibit 5-HT clearance in hippocampus and to produce antidepressant-like effects in the TST.
10538 • J. Neurosci., June 19, 2013 • 33(25):10534 –10543 Horton et al. • Organic Cation Transporters and Antidepressants
did not produce significant effects on time spent immobile com-
pared with saline-treated mice. However, in contrast to wild-type
mice, we found that D-22 failed to enhance the ability of fluvox-
amine to reduce time spent immobile in the TST in OCT3 KO
mice (Fig. 4A). These results suggest a key role for OCT3 in me-
diating this effect of D-22.
To confirm that this result was not due to reduced sensitivity
of OCT3 KO mice to fluvoxamine, we performed dose–response
studies and found that, like in wild-type mice, 10 mg/kg fluvox-
amine was the largest dose that did not have significant effects by
itself in the TST in OCT3 KO mice. Immobility time following
vehicle injection in OCT3 KO mice was 127  19 s (n  10)
(compared with 112  18 s in wild-type mice, Fig. 3, legend).
Similar to wild-type mice, fluvoxamine at doses of 3.2 and 10.0
mg/kg did not significantly influence time spent immobile in
OCT3 KO mice (123  14 s, n  8, and 101  15 s, n  11,
respectively), but significantly reduced immobility time at a dose
of 32.0 mg/kg (47  14 s, n  8, one-way ANOVA, F(3,33)  4.81,
p  0.05). These data indicate that the
inability of D-22 to enhance the anti-
depressant-like effect of fluvoxamine in
the TST in OCT3 KO mice was not due to
a reduction in sensitivity of these mice to
fluvoxamine.
We next investigated if a higher dose of
D-22 (0.32 mg/kg) would enhance the
antidepressant-like effect of fluvoxamine
(10 mg/kg). This dose of D-22 was the
highest that did not decrease locomotion
in wild-type mice. We found that this dose
of D-22 did enhance the ability of fluvox-
amine to reduce time spent immobile in
OCT3 KO mice (Fig. 4A; one-way
ANOVA, F(3,35)  3.49, p  0.05); how-
ever, the magnitude of this enhancement
was not as pronounced as that produced
by the lower dose of D-22 in wild-type
mice (Fig. 3A). In OCT3 KO mice given
D-22 (0.32 mg/kg) together with fluvox-
amine, time spent immobile decreased to
60  15 s (47  12% vehicle control, n 
10), whereas in wild-type mice D-22 (0.1
mg/kg) given in combination with fluvox-
amine decreased immobility time essen-
tially maximally (to 14  8 s, or 12  7%
vehicle control, n  7). An unpaired t test
showed this difference to be significant
(t(15)  2.29, p  0.05). These data suggest
that OCT3 plays a predominant role in
mediating the ability of D-22 to enhance
the antidepressant-like effect of fluvoxamine in the TST, but that
D-22 can also produce this effect by actions at sites other than
OCT3, albeit with lesser potency.
To examine whether the loss of antidepressant-like effect of
the combination of D-22 (0.1 mg/kg) and fluvoxamine in the TST
was associated with a reduced ability of the drug combination to
inhibit 5-HT uptake in OCT3 KO mice, we used high-speed chro-
noamperometry to measure 5-HT clearance in the CA3 region of
hippocampus under the same dose and injection-test interval as
used previously. In contrast to the behavioral data, this drug
combination inhibited 5-HT clearance in OCT3 KO mice simi-
larly to that in wild-type mice (compare Figs. 3B, 4B). As we
found in wild-type mice, D-22 (0.1 mg/kg) had no effect on 5-HT
clearance, whereas fluvoxamine (10 mg/kg), which did not pro-
duce statistically significant effects in the TST, significantly inhib-
ited clearance of intrahippocampally applied 5-HT in OCT3 KO
mice. D-22 (0.1 mg/kg) enhanced fluvoxamine-induced inhibi-
Figure 4. D-22 enhancement of the antidepressant-like effect of fluvoxamine in the TST is attenuated in OCT3 KO mice, whereas
D-22 enhancement of the 5-HT clearance inhibiting effect fluvoxamine remains intact. A, Doses of D-22 (0.1 and 0.32 mg/kg) and
fluvoxamine (10 mg/kg) by themselves did not significantly change time spent immobile in the TST compared with saline-injected
control mice. In contrast to wild-type mice (Fig. 3A), a dose of 0.1 mg/kg D-22 did not decrease immobility time when given
together with fluvoxamine; however, a significant reduction in immobility time resulted when a higher dose of D-22 (0.32 mg/kg)
was given with fluvoxamine. Data are expressed as mean  SEM percentage of time (s) immobile under saline control conditions
(127  19 s); n  8 –11 per treatment condition; one-way ANOVA, F(3,35)  3.17, p  0.015; Newman–Keuls post hoc test, *p 
0.05, from saline and D-22 counterparts. B, In a separate group of mice, using the injection-test intervals as for the TST, systemic
administration of D-22 (0.1 mg/kg) enhanced fluvoxamine (10 mg/kg)-induced inhibition of 5-HT clearance in hippocampus. Data
are expressed as a percentage of baseline T80 values (i.e., prevehicle or drug injection T80 clearance times for 5-HT)  SEM; n 
6 –7 per treatment condition; one-way ANOVA, F(3,25)  12.34, p  0.01; Newman–Keuls post hoc test, *p  0.05, **p  0.001
versus saline; #p  0.05 versus fluvoxamine.
Table 1. D-22 together with fluvoxamine does not produce elements of the serotonin syndrome, unlike the 5-HT1A receptor agonist 8-OH-DPAT and the 5-HT precursor,
5-HTP
Element of the 5-HT syndrome Saline (Tween 80)





(100 mg/kg) F 	4,18
 p value
Hindlimb abduction 0.2  0.2 (2.0  1.5) 0.2  0.2 5.0  1.0* 4.2  1.1* 7.4 0.001
Low body posture 0  0 (0  0) 0  0 4.4  1.2* 4.2  0.9* 10.7 0.001
Straub tail 0  0 (0  0) 0  0 2.0  0.9* 1.6  0.6 4.4 0.012
Tremor 0  0 (0  0) 0  0 1.6  0.7* 0.4  0.3 4.0 0.017
Backward movement 0  0 (0  0) 0.2  0.2 1.0  0.5* 0  0 3.4 0.031
Head weaving 0  0 (0  0) 0  0 0.6  0.6 0  0 0.9 0.495
Forepaw treading 0  0 (0  0) 0  0 0.2  0.2 0  0 0.9 0.495
Data are expressed as mean score  SEM; n  5 per treatment group, except 5% Tween 80 vehicle, n  3; one-way ANOVA, followed by multiple comparisons with Newman–Keuls test. *Significantly different from saline, 5% Tween 80
vehicle and from D-22  fluvoxamine.
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tion of 5-HT clearance in OCT3 KO mice (one-way ANOVA,
F(3,25)  12.34, p  0.05).
Baseline (i.e., predrug) T80 values in OCT3 KO mice did not
differ significantly (p  0.13) among treatment groups and av-
eraged 86  6 s (n  26), a value comparable to that obtained
in wild-type mice (90  4 s, n  69). Likewise, baseline (i.e.,
predrug) signal amplitude values did not differ significantly
( p  0.40) among OCT3 KO mice treatment groups and av-
eraged 0.63  0.03 M, comparable to that in wild-type mice
(0.64  0.02 M).
Discussion
The major finding of the present studies is that the 5-HT clear-
ance inhibiting and antidepressant-like effects of the SSRI fluvox-
amine can be significantly augmented by coadministration of
D-22. These data suggest that D-22-sensitive transporters may
limit the ability of SSRIs to increase extracellular 5-HT and thus,
limit their ability to produce antidepressant effects. D-22-
sensitive transporters, such as OCTs and PMAT, may be useful
targets for the development of new antidepressant medications to
improve the therapeutic utility of SSRIs.
Implications for understanding the relationship between the
ability of SSRIs to inhibit serotonin clearance and to produce
antidepressant-like effects
An especially intriguing finding was the significant effect of the
combination of fluvoxamine and D-22 to increase both the time
course for 5-HT clearance and signal amplitude produced by
5-HT locally applied into the CA3 region of hippocampus. Pre-
viously, using similar approaches, we and others have not rou-
tinely observed an increase in amplitude of the 5-HT signal
following administration of fluvoxamine. This has been a puz-
zling observation given that one would expect blockade of a
transporter to increase both the clearance time and signal ampli-
tude of exogenously applied neurotransmitter. Indeed, this is
true for dopamine (DA) signals following blockade of the DA
transporter (DAT) with drugs such as cocaine and nomifensine
in DAT-rich regions, such as striatum and nucleus accumbens
(Zahniser et al., 1999). This paradoxical lack of effect of SSRIs
to increase 5-HT signal amplitude may well be attributed to
the presence of D-22-sensitive transporters (OCTs and
PMAT) and their expression level relative to SERT in hip-
pocampus. As discussed earlier, these low-affinity, high-
capacity transporters may become more effective at clearing
5-HT when extracellular 5-HT concentrations rise. Thus, fol-
lowing fluvoxamine, D-22-sensitive transporters may serve to
prevent the 5-HT signal amplitude from increasing. Consis-
tent with this notion is the observation that the effect of flu-
voxamine on 5-HT clearance is most pronounced toward the
tail of the signal, i.e., when the 5-HT concentration has fallen
below the “reach” of low-affinity, high-capacity D-22-
sensitive transporters (Fig. 1A). Thus, the combined effect of
an SSRI and blocker of D-22-sensitive transporters is to not
only further increase the duration that 5-HT remains in the
extracellular fluid, but also to further increase the concentra-
tion (Daws et al., 2013).
Increased extracellular levels of 5-HT are considered to be an
important trigger for ultimate therapeutic benefit in humans.
Supporting this idea, our findings in wild-type mice show that
antidepressant-like activity in the TST is positively correlated
with the ability of a drug, or drug combination, to inhibit
clearance of 5-HT in CA3 region of hippocampus (Fig. 3C).
However, this was not the case in OCT3 KO mice, where the
ability of D-22 to enhance the antidepressant-like effect of
fluvoxamine in the TST was greatly attenuated, and yet inhi-
bition of 5-HT clearance in the CA3 region of hippocampus
was equivalent to that in wild-type mice. Thus, OCT3 appears
to play a prominent role in mediating effects of D-22 in the
TST, but does not appear to be involved in mediating the effect
of D-22 to enhance fluvoxamine-induced inhibition of 5-HT
clearance in the CA3 region of hippocampus. Together, these
results indicate that antidepressant-like effects of a given treat-
ment in the TST are not necessarily related to its ability to
inhibit 5-HT clearance in the CA3 region of hippocampus.
This raises the possibility that D-22’s augmentation of the
antidepressant-like effect of fluvoxamine in the TST is medi-
ated by brain regions other than, or in addition to the CA3
region of hippocampus, and/or by its activity at other sites,
possibly other OCT subtypes or PMAT, where it may inhibit
uptake of 5-HT as well as other biogenic amines considered
important in antidepressant-like response, discussed below.
Implications for increasing the clinical effects
of antidepressants
The lack of symptom relief in many patients treated with cur-
rently available antidepressants emphasizes the need for novel
pharmacological approaches with improved efficacy to treat
depression. Our findings support D-22-sensitive uptake mecha-
nisms as additional targets for the discovery of novel antidepres-
sant therapies to maximize blockade of 5-HT uptake in brain.
However, in addition to 5-HT, D-22-sensitive OCTs and PMAT
are also low-affinity, high-capacity transporters for norepineph-
rine (NE) and DA (Wu et al., 1998; Amphoux et al., 2006; Cui et
al., 2009; Bacq et al., 2012). Thus, while SSRIs have been the focus
of this study, our results may generalize to other classes of anti-
depressants, including selective NE reuptake inhibitors, which
block NE uptake via the NE transporter (NET), dual 5-HT-NE
reuptake inhibitors, and triple-uptake inhibitors, which block
transport of 5-HT, NE, and DA via their high-affinity transport-
ers, SERT, NET, and DAT. To date, antidepressants that block
SERT, NET, and DAT are thought to have the greatest clinical
efficacy (Sulzer and Edwards, 2005; Chen and Skolnick, 2007).
This may be in part attributed to the promiscuity that exists
among SERT, NET, and DAT, which are all capable of low-
affinity transport of their non-native biogenic amines (Pacholc-
zyk et al., 1991; Daws et al., 1998; Norrholm et al., 2007; Rice and
Cragg, 2008; Daws, 2009), as well as to the likelihood that suc-
cessful treatment of depression requires targeting multiple neu-
rotransmitter systems. Regardless, our findings suggest that the
presence of D-22-sensitive transporters might also limit thera-
peutic efficacy of antidepressants other than SSRIs, and that
blockade of D-22-sensitive transporters might serve to enhance
their therapeutic efficacy by enhancing their ability to inhibit
uptake of NE and DA, as well as 5-HT. Consistent with this idea,
Hagan et al. (2011), using rotating disk voltammetry to measure
5-HT uptake into whole brain synaptosomes, showed that com-
plete blockade of 5-HT uptake could only be achieved after incu-
bating synaptosomes with blockers of SERT, NET, and DAT
together with D-22. Thus, in terms of elevating extracellular lev-
els of 5-HT and other biogenic amines to those that effectively
treat depression, several lines of evidence, including the present
study, point to blockade of D-22-sensitive transporters as a
promising strategy.
In addition to being a potent blocker of low-affinity, high-
capacity 5-HT transporters, D-22 has -1-adrenoceptor antago-
nist properties (Russ et al., 1996). -1 antagonism is unlikely to
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mediate the enhancement by D-22 of fluvoxamine-induced inhi-
bition of 5-HT clearance and antidepressant-like effects, because
the -1-adrenoceptor antagonist prazosin reportedly produces
effects that are unlike those observed here with D-22. For exam-
ple, prazosin decreases SSRI-induced increases of 5-HT levels
(Rea et al., 2010), whereas D-22 enhanced the fluvoxamine-
induced increase of 5-HT levels. In addition, prazosin increases
immobility in the TST (Stone and Quartermain, 1999), whereas
D-22 was inactive in this test when given alone at doses that
enhanced effects of fluvoxamine. Finally, prazosin can block
behavioral actions of antidepressants (Kostowski, 1985),
whereas D-22 enhanced the antidepressant-like effects of flu-
voxamine. Thus, it appears unlikely that -1 antagonist prop-
erties underlie the ability of D-22 to enhance effects of
fluvoxamine. Recently, the D-22 congener disprocynium-24
(D-24) has been reported to have antagonist properties not
only at -1 receptors, but also at -2 receptors (Amphoux et
al., 2010). It is presently unknown whether D-22 shares -2
antagonist properties with D-24. If it does, these properties are
unlikely to account for the effects of D-22 observed here, be-
cause the -2 antagonist yohimbine does not affect 5-HT
clearance (Ansah et al., 2003), and yohimbine increases im-
mobility time in the TST (Ferrari et al., 1991). Together, there
is evidence that D-22 has -1-adrenoceptor antagonist prop-
erties, and evidence that -1 antagonism produces effects that
are opposite to those observed here with D-22. Thus, analogs
of D-22 that lack -1 antagonist properties may enhance ef-
fects of SSRIs even more markedly than D-22.
Although the idea of low-affinity, high-capacity transporters
for 5-HT is not new, heralding back to the 1960s and 1970s when
several groups reported promiscuous uptake of 5-HT by the so-
called “uptake-2” transporter (Bertler et al., 1964; Fuxe et al.,
1967; Lichtensteiger et al., 1967; Shaskan and Snyder, 1970), the
identity of the transporter(s) has remained under some debate
(Daws, 2009). In 2004, Schildkraut and Mooney proposed the
extraneuronal monoamine transporter (uptake-2) as a target for
development of more rapidly acting antidepressants, but still, the
precise identity of “uptake-2” remained controversial. Since that
time, several reports have emerged pointing to D-22-sensitive
OCTs and PMAT as being primary uptake-2 (i.e., low-affinity,
high-capacity) transporters for the biogenic amines (for review,
see Daws, 2009). The challenge now will be to determine which of
these might be the best to target for the discovery of new antide-
pressant drugs. While this field is still in its infancy OCT3 and
more recently, OCT2, are emerging as leading candidates (Kitai-
chi et al., 2005; Baganz et al., 2008; Bacq et al., 2012). The mark-
edly reduced potency of D-22 to enhance the antidepressant-like
effect of fluvoxamine in the TST in OCT3 KO mice provides the
first direct evidence that OCT3 is important for this action of
D-22. Our behavioral and neurochemical results encourage fur-
ther research into the role of D-22-sensitive transporters in reg-
ulating biogenic amine neurotransmission and behavior.
Selective targeting of different OCT subtypes or PMAT may be a
valid strategy to discover treatments with improved antidepres-
sant efficacy, either as a cotreatment with existing antidepressant
drugs or as novel 5-HT reuptake inhibitors with additional OCT
or PMAT blocking properties.
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Montañez S, Owens WA, Gould GG, Murphy DL, Daws LC (2003) Exag-
gerated effect of fluvoxamine in heterozygote serotonin transporter
knockout mice. J Neurochem 86:210 –219. Medline
Norrholm SD, Horton DB, Dwoskin LP (2007) The promiscuity of the do-
pamine transporter: implications for the kinetic analysis of [ 3H]serotonin
uptake in rat hippocampal and striatal synaptosomes. Neuropharmacol-
ogy 53:982–989. CrossRef Medline
Pacholczyk T, Blakely RD, Amara SG (1991) Expression cloning of a
cocaine- and antidepressant-sensitive human noradrenaline transporter.
Nature 350:350 –354. CrossRef Medline
Perez XA, Andrews AM (2005) Chronoamperometry to determine differen-
tial reductions in uptake in brain synaptosomes from serotonin trans-
porter knockout mice. Anal Chem 77:818 – 826. CrossRef Medline
Rea K, Folgering J, Westerink BH, Cremers TI (2010) Alpha1-
adrenoceptors modulate citalopram-induced serotonin release. Neuro-
pharmacology 58:962–971. CrossRef Medline
Rice ME, Cragg SJ (2008) Dopamine spillover after quantal release: rethink-
ing dopamine transmission in the nigrostriatal pathway. Brain Res Rev
58:303–313. CrossRef Medline
Russ H, Friedgen B, Königs B, Schumacher C, Graefe KH, Schömig E (1996)
Pharmacokinetic and alpha 1-adrenoceptor antagonistic properties of
two cyanine-type inhibitors of extraneuronal monoamine transport.
Naunyn Schmiedebergs Arch Pharmacol 354:268 –274. Medline
Schildkraut JJ, Mooney JJ (2004) Toward a rapidly acting antidepressant:
the normetanephrine and extraneuronal monoamine transporter (uptake
2) hypothesis. Am J Psychiatry 161:909 –911. CrossRef Medline
Schömig E, Babin-Ebell J, Russ H (1993) 1,1-Diethyl-2,2-cyanine (decy-
nium22) potently inhibits the renal transport of organic cations. Naunyn
Schmiedebergs Arch Pharmacol 347:379 –383. CrossRef Medline
Schömig E, Lazar A, Gründemann D (2006) Extraneuronal monoamine
transporter and organic cation transporters 1 and 2: a review of transport
efficiency. Handb Exp Pharmacol 175:151–180. CrossRef Medline
Shaskan EG, Snyder SH (1970) Kinetics of serotonin accumulation into
slices from rat brain: relationship to catecholamine uptake. J Pharmacol
Exp Ther 175:404 – 418. Medline
Sternbach H (1991) The serotonin syndrome. Am J Psychiatry 148:705–
713. Medline
Steru L, Chermat R, Thierry B, Simon P (1985) The tail suspension test: a
10542 • J. Neurosci., June 19, 2013 • 33(25):10534 –10543 Horton et al. • Organic Cation Transporters and Antidepressants
new method for screening antidepressants in mice. Psychopharmacology
85:367–370. CrossRef Medline
Stone EA, Quartermain D (1999) Alpha-1-noradrenergic neurotransmis-
sion, corticosterone, and behavioral depression. Biol Psychiatry 46:1287–
1300. CrossRef Medline
Sulzer D, Edwards RH (2005) Antidepressants and the monoamine mas-
querade. Neuron 46:1–2. CrossRef Medline
Vialou V, Balasse L, Dumas S, Giros B, Gautron S (2007) Neurochemical
characterization of pathways expressing plasma membrane monoamine
transporter in the rat brain. Neuroscience 144:616 – 622. CrossRef
Medline
Vialou V, Balasse L, Callebert J, Launay JM, Giros B, Gautron S (2008) Al-
tered aminergic neurotransmission in the brain of organic cation trans-
porter 3-deficient mice. J Neurochem 106:1471–1482. Medline
Williams JM, Owens WA, Turner GH, Saunders C, Dipace C, Blakely RD,
France CP, Gore JC, Daws LC, Avison MJ, Galli A (2007) Hypoinsuline-
mia regulates amphetamine-induced reverse transport of dopamine.
PLoS Biol 5:e274. CrossRef Medline
Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ,
Ganapathy V (1998) Identity of the organic cation transporter OCT3
as the extraneuronal monoamine transporter (uptake2) and evidence
for the expression of the transporter in the brain. J Biol Chem 273:
32776 –32786. CrossRef Medline
Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J,
Conway SJ, Ganapathy V (1999) Functional characteristics and tis-
sue distribution pattern of organic cation transporter 2 (OCTN2) an
organic cation/carnitine transporter. J Pharmacol Exp Ther 290:
1482–1492. Medline
Wultsch T, Grimberg G, Schmitt A, Painsipp E, Wetzstein H, Breitenkamp
AF, Gründemann D, Schömig E, Lesch KP, Gerlach M, Reif A (2009)
Decreased anxiety in mice lacking organic cation transporter 3. J Neural
Transm 116:689 – 697. CrossRef Medline
Zahniser NR, Larson GA, Gerhardt GA (1999) In vivo dopamine clear-
ance rate in rat striatum: regulation by extracellular dopamine con-
centration and dopamine transporter inhibitors. J Pharmacol Exp
Ther 289:266 –277. Medline
Zwart R, Verhaagh S, Buitelaar M, Popp-Snijders C, Barlow DP (2001) Im-
paired activity of the extraneuronal monoamine transporter systems
known as uptake-2 in Ort3/Slc22a3-deficient mice. Mol Cell Biol 21:
4188 – 4196. CrossRef Medline
Horton et al. • Organic Cation Transporters and Antidepressants J. Neurosci., June 19, 2013 • 33(25):10534 –10543 • 10543
